Lenalidomide and Dinutuximab With or Without Isotretinoin in Treating Younger Patients With Refractory or Recurrent Neuroblastoma
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Cellectar Biosciences, Inc.
Children's Hospital of Philadelphia
University of Florida
Memorial Sloan Kettering Cancer Center
National Institutes of Health Clinical Center (CC)
Dana-Farber Cancer Institute
St. Jude Children's Research Hospital
Baylor College of Medicine
Children's Hospital Los Angeles
Children's National Research Institute
Children's Oncology Group
Baylor College of Medicine
Dana-Farber Cancer Institute
GlaxoSmithKline
National Cancer Institute (NCI)
Baylor College of Medicine
Children's Hospital of Philadelphia
Emory University
Children's Hospital of Philadelphia
Seattle Children's Hospital
Seattle Children's Hospital
Institut Claudius Regaud
St. Jude Children's Research Hospital
National Cancer Institute (NCI)
St. Jude Children's Research Hospital
University Hospital Southampton NHS Foundation Trust
University of Wisconsin, Madison
Novartis
Valent Technologies, LLC
Baylor College of Medicine
New Approaches to Neuroblastoma Therapy Consortium
UNC Lineberger Comprehensive Cancer Center
Orphelia Pharma
Memorial Sloan Kettering Cancer Center
Eli Lilly and Company
Actuate Therapeutics Inc.
Dana-Farber Cancer Institute
National Institutes of Health Clinical Center (CC)
Princess Maxima Center for Pediatric Oncology
New Approaches to Neuroblastoma Therapy Consortium
Kian Immune Cell Company
City of Hope Medical Center
Dana-Farber Cancer Institute
Ascentage Pharma Group Inc.
Baylor College of Medicine
Sun Yat-sen University
New Approaches to Neuroblastoma Therapy Consortium
New Approaches to Neuroblastoma Therapy Consortium
Nanjing Children's Hospital